Presenting a comprehensive survey of the telecommunications industry in Japan, Taplin and Wakui cover the different sectors of the industry - including mobile, broadband and satellite, whilst considering key questions such as the structure and economics of the industry, government policy, and international relations issues connected to the industry. The volume brings together unique analysis by renowned experts in the telecommunications field. One major overall problem is that, unlike many other industries, Japan has lagged behind other countries in telecommunications. Japanese Telecommunications considers why this should be so, showing how far this is attributable to an unmodernized industry structure, and assessing the measures being taken to address the problem. After over a decade of struggle, Japan has recorded rapid uptake of broadband, and Japanese advanced mobile services have become increasingly successful on a global scale. Japan has also undergone regulatory reform, and competition policy is now given top priority by government. Taplin and Wakui examine the most recent developments and provide signposts for the future.

Presenting a comprehensive survey of the telecommunications industry in Japan, Taplin and Wakui cover the different sectors of the industry - including mobile, broadband and satellite, whilst considering key questions such as the structure and economics of the industry, government policy, and international relations issues connected to the industry. The volume brings together unique analysis by renowned experts in the telecommunications field. One major overall problem is that, unlike many other industries, Japan has lagged behind other countries in telecommunications. Japanese Telecommunications considers why this should be so, showing how far this is attributable to an unmodernized industry structure, and assessing the measures being taken to address the problem. After over a decade of struggle, Japan has recorded rapid uptake of broadband, and Japanese advanced mobile services have become increasingly successful on a global scale. Japan has also undergone regulatory reform, and competition policy is now given top priority by government. Taplin and Wakui examine the most recent developments and provide signposts for the future.

This is the first book published that focuses on competition law and policy in the Japanese pharmaceutical sector. It consists of chapters written and edited by academics who research the industry from various perspectives, including economics, competition law, pharmaceutical regulations, and intellectual property law. Competition policies involving pharmaceutical products attract attention from academics and policymakers worldwide. The pharmaceutical industry is regulated by drug laws that vary from country to country and are affected by differing practices and industrial structures. The book begins by examining drug regulations and trade practices in the industry that are peculiar to Japan and its healthcare system. It then presents the Japanese Antimonopoly Act and cases involving it, and discussions of current competition law issues in the Japanese pharmaceutical industry. The book also discusses innovation and intellectual property and economic analyses of pharmaceutical regulations and drug discovery. The chapters include comparative studies on Japanese regulations vs. those in the European Union and the United States. Japan is one of the biggest pharmaceutical markets in the world. With this in mind, the book provides “one-stop shopping” for anyone interested in pharmaceutical regulations in the country. Covering the basics but extending to in-depth explorations of complex problems, this book appeals not only to students and academics, pharmaceutical companies and regulators, but also to those dealing with real-world policy issues that encompass competition policy, intellectual property, and pharmaceutical regulation. Chapter 11 is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com

This is the first book published that focuses on competition law and policy in the Japanese pharmaceutical sector. It consists of chapters written and edited by academics who research the industry from various perspectives, including economics, competition law, pharmaceutical regulations, and intellectual property law. Competition policies involving pharmaceutical products attract attention from academics and policymakers worldwide. The pharmaceutical industry is regulated by drug laws that vary from country to country and are affected by differing practices and industrial structures. The book begins by examining drug regulations and trade practices in the industry that are peculiar to Japan and its healthcare system. It then presents the Japanese Antimonopoly Act and cases involving it, and discussions of current competition law issues in the Japanese pharmaceutical industry. The book also discusses innovation and intellectual property and economic analyses of pharmaceutical regulations and drug discovery. The chapters include comparative studies on Japanese regulations vs. those in the European Union and the United States. Japan is one of the biggest pharmaceutical markets in the world. With this in mind, the book provides "one-stop shopping" for anyone interested in pharmaceutical regulations in the country. Covering the basics but extending to in-depth explorations of complex problems, this book appeals not only to students and academics, pharmaceutical companies and regulators, but also to those dealing with real-world policy issues that encompass competition policy, intellectual property, and pharmaceutical regulation. Chapter 11 is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com

This book provides a comparative overview of the rules in EU, US and Japan law on competition. After an overview of the history and the underlying economic issues, it discusses cartels and other agreements restraining competition (ancillary agreements, R&D/specialization agreements, distribution agreements), single-firm conduct (abuse of market power/monopolization), general procedural law and merger control, as well as state measures (regulation, subsidies, etc.) are treated from a comparative perspective. In each case, the presentation of the legal system is supplemented by examples from the case law. With focus on the protection of competition in digital markets new regulatory approaches (e.g., the EU Digital Markets Act and the comparable US regulatory initiatives) are compared and current legal developments in other jurisdictions are also addressed.